What is Neuphoria Therapeutics Inc?
, a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
, a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 13.80M.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.